The Lower Health Care Costs Act, under consideration in both the House and Senate, includes a provision (Section 407 — the BLOCKING Act) that would significantly harm the competition that lowers prescription drug prices for America’s patients and taxpayers. AAM CEO Chester “Chip” Davis, Jr. wrote to President Trump to urge him to oppose the BLOCKING Act.
The BLOCKING Act would undermine the only incentive generic drug developers have to file their applications with the FDA as early as possible — to bring savings to patients and taxpayers as quickly as possible. This proposal would result in delayed price competition from FDA-approved generic medicines and longer monopolies for expensive brand-name drugs.
Mr. President: Please block the BLOCKING Act so Congress does not destroy your pro-competitive policies that have produced such savings over the last three years.
